Literature DB >> 29523656

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Marieke F Fransen1, Hreinn Benonisson2, Wendy W van Maren1, Heng Sheng Sow2, Cor Breukel2, Margot M Linssen2, Jill W C Claassens2, Conny Brouwers2, Jos van der Kaa2, Marcel Camps1, Jan Willem Kleinovink1, Kelly K Vonk2, Sandra van Heiningen2, Ngaisah Klar3, Lianne van Beek2, Vanessa van Harmelen2, Lucia Daxinger2, Kutty S Nandakumar4,5, Rikard Holmdahl4, Chris Coward6, Qingshun Lin7, Sachiko Hirose8, Daniela Salvatori9, Thorbald van Hall10, Cees van Kooten3, Piero Mastroeni6, Ferry Ossendorp1, J Sjef Verbeek11.   

Abstract

By their interaction with IgG immune complexes, FcγR and complement link innate and adaptive immunity, showing functional redundancy. In complement-deficient mice, IgG downstream effector functions are often impaired, as well as adaptive immunity. Based on a variety of model systems using FcγR-knockout mice, it has been concluded that FcγRs are also key regulators of innate and adaptive immunity; however, several of the model systems underpinning these conclusions suffer from flawed experimental design. To address this issue, we generated a novel mouse model deficient for all FcγRs (FcγRI/II/III/IV-/- mice). These mice displayed normal development and lymphoid and myeloid ontogeny. Although IgG effector pathways were impaired, adaptive immune responses to a variety of challenges, including bacterial infection and IgG immune complexes, were not. Like FcγRIIb-deficient mice, FcγRI/II/III/IV-/- mice developed higher Ab titers but no autoantibodies. These observations indicate a redundant role for activating FcγRs in the modulation of the adaptive immune response in vivo. We conclude that FcγRs are downstream IgG effector molecules with a restricted role in the ontogeny and maintenance of the immune system, as well as the regulation of adaptive immunity.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Year:  2018        PMID: 29523656      PMCID: PMC5896742          DOI: 10.4049/jimmunol.1700429

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  On-target and off-target-based toxicologic effects.

Authors:  Daniel G Rudmann
Journal:  Toxicol Pathol       Date:  2012-10-19       Impact factor: 1.902

Review 2.  Antibodies as natural adjuvants.

Authors:  Birgitta Heyman
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

3.  IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation.

Authors:  Esther D Quakkelaar; Marieke F Fransen; Wendy W C van Maren; Joost Vaneman; Nikki M Loof; Sandra H van Heiningen; J Sjef Verbeek; Ferry Ossendorp; Cornelis J M Melief
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

4.  Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

Authors:  J M Ahearn; M B Fischer; D Croix; S Goerg; M Ma; J Xia; X Zhou; R G Howard; T L Rothstein; M C Carroll
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

Review 5.  ITAM-based signaling beyond the adaptive immune response.

Authors:  Szabina Fodor; Zoltán Jakus; Attila Mócsai
Journal:  Immunol Lett       Date:  2005-11-28       Impact factor: 3.685

6.  IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Authors:  Chang-Han Lee; Gabrielle Romain; Wupeng Yan; Makiko Watanabe; Wissam Charab; Biliana Todorova; Jiwon Lee; Kendra Triplett; Moses Donkor; Oana I Lungu; Anja Lux; Nicholas Marshall; Margaret A Lindorfer; Odile Richard-Le Goff; Bianca Balbino; Tae Hyun Kang; Hidetaka Tanno; George Delidakis; Corrine Alford; Ronald P Taylor; Falk Nimmerjahn; Navin Varadarajan; Pierre Bruhns; Yan Jessie Zhang; George Georgiou
Journal:  Nat Immunol       Date:  2017-06-12       Impact factor: 25.606

7.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

8.  Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake.

Authors:  Ayumi Yada; Shin Ebihara; Kimio Matsumura; Shota Endo; Tsutomu Maeda; Akira Nakamura; Kenichi Akiyama; Setsuya Aiba; Toshiyuki Takai
Journal:  Cell Immunol       Date:  2003-09       Impact factor: 4.868

9.  A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes.

Authors:  Nadine van Montfoort; Judith M H de Jong; Danita H Schuurhuis; Ellen I H van der Voort; Marcel G M Camps; Tom W J Huizinga; Cees van Kooten; Mohamed R Daha; J Sjef Verbeek; Ferry Ossendorp; René E M Toes
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

Review 10.  Antigen cross-presentation of immune complexes.

Authors:  Barbara Platzer; Madeleine Stout; Edda Fiebiger
Journal:  Front Immunol       Date:  2014-04-01       Impact factor: 7.561

View more
  7 in total

1.  Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.

Authors:  Xiaojie Yu; H T Claude Chan; Hayden Fisher; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Ruth R French; Patrick J Duriez; Leon R Douglas; Vikki English; J Sjef Verbeek; Ann L White; Ivo Tews; Martin J Glennie; Mark S Cragg
Journal:  Cancer Cell       Date:  2020-05-21       Impact factor: 31.743

2.  The essential role of complement in antibody-mediated resistance to Salmonella.

Authors:  Omar Rossi; Chris Coward; Yun Shan Goh; Jill W C Claassens; Calman A MacLennan; Sjef J Verbeek; Pietro Mastroeni
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

Review 3.  The Complex Association of FcγRIIb With Autoimmune Susceptibility.

Authors:  J Sjef Verbeek; Sachiko Hirose; Hiroyuki Nishimura
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

4.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Authors:  Xiaojie Yu; Sonya James; James H Felce; Blanka Kellermayer; David A Johnston; H T Claude Chan; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Yasunori Watanabe; Max Crispin; Ruth R French; Patrick J Duriez; Leon R Douglas; Martin J Glennie; Mark S Cragg
Journal:  Commun Biol       Date:  2021-06-23

5.  Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders.

Authors:  April M Huseby Kelcher; Carly A Baehr; Fatima A Hamid; Geoffrey T Hart; Marco Pravetoni
Journal:  J Immunol       Date:  2021-07-19       Impact factor: 5.426

6.  FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Authors:  Ramon Arens; Sjef Verbeek; Hreinn Benonisson; Heng Sheng Sow; Cor Breukel; Jill W C Claassens; Conny Brouwers; Margot M Linssen; Anke Redeker; Marieke F Fransen; Thorbald van Hall; Ferry Ossendorp
Journal:  Oncotarget       Date:  2018-06-29

7.  Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Authors:  Mehmet Sahin; Melissa M Remy; Benedict Fallet; Rami Sommerstein; Marianna Florova; Anna Langner; Katja Klausz; Tobias Straub; Mario Kreutzfeldt; Ingrid Wagner; Cinzia T Schmidt; Pauline Malinge; Giovanni Magistrelli; Shozo Izui; Hanspeter Pircher; J Sjef Verbeek; Doron Merkler; Matthias Peipp; Daniel D Pinschewer
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.